参考文献
[1] Pratt E, et al. Diabetes Obes Metab. 2023;25(9):2642-2649.
[2] Safety, tolerability, pharmacokinetics, and pharmacodynamics of orforglipron: A multiple dose titration study in Chinese participants with obesity or overweight with weight-related comorbidities (Poster Abstract No. 2624-P). Poster presented at the American Diabetes Association Annual Meeting.
[3] Efficacy and safety of Orforglipron vs Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5. Presented at: American Diabetes Association 86th Scientific Sessions; 2026 Jun 5-8; New Orleans, LA, USA.
[4] Health-Related Quality of Life (HRQoL) in People with Type 2 Diabetes (T2D) Receiving the Once-Daily, Oral, Non-Peptide GLP-1 RA Orforglipron in ACHIEVE-2 and -3. Presented at: American Diabetes Association 86th Scientific Sessions; 2026 Jun 5-8; New Orleans, LA, USA.
[5] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(13):1209-1221.
[6] Efficacy and safety of once-daily oral orforglipron compared with dapagliflozin in adults with type 2 diabetes (ACHIEVE-2): a multinational, multicentre, randomised, open-label, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(11):805-816.
[7] Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10500):1147-1160.
[8] Efficacy and safety of once-daily oral orforglipron in adults with type 2 diabetes inadequately controlled with metformin plus basal insulin (ACHIEVE-5): a multinational, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2026;406(10499):2927-2944.
[9] Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806.
[10] Orforglipron for weight management in adults with obesity and type 2 diabetes (ATTAIN-2): a 72-week, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;396(10265):2011-2022.
[11] PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732.
[12] Efficacy and safety of oral semaglutide versus sitagliptin in patients with type 2 diabetes (PIONEER 2): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10193):193-202.
[13] Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):503-513.
[14] Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528-539.
[15] Orforglipron and markers of insulin sensitivity and beta-cell function by prediabetes status in adults with obesity: a post hoc analysis of the ATTAIN-1 trial. Poster presented at: American Diabetes Association Annual Meeting. Abstract 1666-P.
